| 초록 |
Neutrophils are the most abundant human immune cells and make up over 70% of all human leukocytes. They elicit adaptive immune effector functions including ADCC and ADCP as well as a variety of innate immune functions such as degranulation, ROS production, and necrosis. Therefore, harnessing neutrophils has been considered one of the most attractive options to overcome the limitations of conventional therapeutic antitumor agents. In particular, among the receptors expressed on neutrophil, CD89 (Fc alpha receptor) activates neutrophils for the clearance of aberrant tumor cells through “trogoptosis”. For enhanced antitumor potency, we attempted to develop bispecific antibodies that co-engage CD89 and a tumor associated antigen simultaneously. Currently, five monoclonal human antibodies that bind to CD89 have been isolated, and we are in process to engineer the resulting antibodies towards neutrophil engaging next-generation therapeutic bispecific antibodies with high antitumor potency. |
